Liver Specialists of Texas Articles RSS Feed

Hepatitis C Research Opportunities with Dr. Joseph Galati: 2013

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 20 Jan 2013 04:00:00 GMT

Listed below are the updated hepatitis C research protocols that Liver Specialists of Texas and Dr. Galati are currently conducting. The studies are in various stages of enrollment, and some may have already met the limit of how many patients we can enroll. A PDF version is available here.

New studies are being added every few weeks, so depending on your situation, and past experience with hepatitis C treatment, new opportunities may be available soon.

Currently, the ongoing studies are making use of both interferon based therapies, as well as interferon-free therapies. It is probable that the next wave of FDA approvals will be for the interferon-free protocols.

Kindly call Dee Wade at 713-794-0700 to inquire about hepatitis C research opportunities.

Research Specialists of Texas

List of Ongoing Studies

No.	Sponsor	Protocol #	Protocol Title:	Status
1	Abbott	M12-114	A Blinded Randomized, Placebo-Controlled, Dose-Ranging study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination with Peginterferon a-2a and Ribavirin (pegINF/RBV) in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.	Open/Follow Up
2	Hoffman-La Roche, Inc.	598-505	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of Safety, Efficacy, and Pharmacokinetics of ANA598 Administered with Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients with Chronic Hepatitis C Infection.	Open/Follow Up
3	Bristol Myers S	AI444-038	Open-Label, Single Arm Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos, and White-Caucasians with Chronic Hepatitis C Genotype 1 Infection.	Open/Follow Up
4	Bristol Myers S	AI444-052	A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir In combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment- Naïve Patients with Chronic Hepatitis-C	Open/ Follow Up
5	Bristol Myers S	AI443-1014	Open-Label, Multiple Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Co administration of BMS-650032, BMS-7900052, and BMS-791325 when administered for 24 or 12 weeks in Treatment-Naïve Subjects Infected with Hepatitis C Virus Genotype 1	Open/Enrolling
5	Gilead	GS-US-337-0102	A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir /GS-5885 Fixed-Dose Combination+ Ribavirin for 12 or 24 Weeks in Treatment-Naïve Subjects with Chronic HCV Genotype 1 Infection	Open/ On drug Treatment/FU
6	Gilead	GS-US-334-0110	A Phase 3, Multicenter, Open Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Week in Treatment-Naïve Subjects with Chronic Genotype 1,4, 5, or 6 HCV Infection	Open/ Follow Up
7	Gilead	GS-US-248-0121	A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 with Peginterferon Alfa 2a (PEG) and Ribavirin (RBV) in Treatment-Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype	Open/Follow UP
8	Gilead	GS-US-248-0122 (Registry Study)	A Long Term Follow Up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic HepatitisC Infection	Open
9	Gilead	GS-US-248-0123 (Registry Study)	A Long Term Follow up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C	Open
10	Gilead	GS-US-256-0124	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus Infection	Open/ subjects completed study.
11	Gilead	GS-US-196-0140	A Phase 2b, Randomized, Double-Blind, Placebo Controlled Trial Evaluating 16 and 24 Weeks of a Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection	Open/ Subjects finished Study.
12	Gilead	GS-US-256-0148	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 or GS-9256 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C	Open/ Follow up 2 Subjects
13	Gilead	GS-US- 337-0109	A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed Dose Combination + Ribavirin for 12 and 24 Weeks in Treatment-Experience Subjects with Chronic Genotype 1 HCV Infection	Open/ Screening
14	Gilead	P7977-1231	A Phase III Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 weeks compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment Naïve Patients with Chronic Genotype 2or 3 HCV Infection	Open/ Follow Up
15	U. Florida/U. NC	HCV-TARGET	Hepatitis C Therapeutic Registry and Research Network- A Longitudinal, Observational Study	Open/ Ready for Screening
16	Beckman Coulter	HCV-01-11	Multicenter, Prospective Evaluation of the Beckman Coulter DxN-HCV Viral Load Assay as an Aid in the Management of HCV- Infected Individual Undergoing Antiviral	Open/Ready for Screening
17	Merck	5172-003	A Dose Ranging Study to Test the Safety, Tolerability and Effectiveness of Different Doses of MK-5172 When Given with Peginterferon alfa-2b and Ribavirin in Patients with Hepatitis C Virus Infection	Open/ Follow Up
18	Merck	7009-028	A Phase 2 Open Label Study of MK 7009 Administered Concomitantly with Pegylated Interferon Alfa 2a and Ribavirin to Patients with Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials	Open/ Follow Up
19	Merck	5172-017 (Roll Over)	A Long Term Follow Up Study to Evaluate the Durability of Virologic Response and /or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have been Previously Treated with MK5172 in a Prior Clinical Trial	IRB Approved. Sponsor Site Activation.
20	Novartis	CDEB025A2301	A Randomized Double Blind,Placebo- Controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination with Peginterferon alpha 2a (PEG-IFN) and Ribavirin in hepatitis C Genotype 1 treatment naïve patients.	Open/ Follow Up
21	Novartis	CDEB025A2312 (Roll Over)	A Multi-Centre 3 Year Follow Up Study to assess the Durability of Sustained Virologic response in Alisporivir treated Chronic Hepatitis C patients	Open/ Follow Up
22	Novartis	CDEB025A2313 (Roll Over)	A Multi-Centre 3 Year follow up study to assess the viral activity in patients Who failed to achieve sustained virologic response in Novartis sponsored Alisporivir –studies for chronic Hepatitis C patients	Open
23	Schering-Plough	P05063	Term Follow Up of Subjects in a Phase 1,2,or 3 Clinical Trial in Which Boceprevir or Narlaprevir was administer red for the treatment of Chronic Hepatitis C	Open/ Follow Up
24	Schering-Plough	P05514	A single Arm Study to Provide Boceprevir Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in PREVIOUS Schering-Plough Boceprevir Studies	Open/ Subjects Completed study
25	Tibotec	TMC435-TiD16-C213	A Phase III Open Label Trial of TMC435 In Combination with Peginterferon And Ribavirin for HCV Genotype 1 infected Subjects who Participated in the placebo group of a Phase II/III TMC435 study (C201, C205, C206, C208, C216 or HPC3007) or who received short term (up to 14 days) direct acting antiviral treatment for hepatitis C infection in a selected Jansen R&D Ireland-Sponsored phase I Study.	Open
26	Tibotec	TMC435-TidP16-C216	A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 versus placebo as part of a treatment regimen including peginterferon α-2a (Pegasys®) and ribavirin (Copegus®) or peginterferon α-2b (PegIntron®) and ribavirin (Rebetol®) in treatment-naïve, genotype 1, hepatitis C-infected subjects.	Open/ Subjects Completed study
27	Tibotec	TMC435HPC3007	A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected subjects who relapsed after previous interferon-based therapy.	Open/ Subjects Completed study
28	Tibotec	VX-950-C211	A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection.	Open/Subjects Completed Study Close out visit on 1/31/13
29	Salix Pharmaceuticals, Inc.	RFHE4044	A Multicenter, Randomized, Open, Label, Active Controlled, Trial To Evaluate The Safety And Efficacy If Rifaximin 550 MG With and Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy	IRB Approved Waiting Site Activation.

As of 1/18/13

19-Jan-13 10:00 PM

Dr. Galati and Liver Specialists of Texas: An Introductory Video

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 12 Aug 2012 04:00:00 GMT

Below is a brief video produced by Liver Specialists of Texas discussing the various services that Dr. Galati and his staff perform.

11-Aug-12 11:00 PM

Liver Specialists of Texas is Moving Office Locations

Joseph Galati, M.D. - noemail@texasliver.com — Wed, 13 Jun 2012 20:00:00 GMT

Effective June 14, 2012, our office location is relocating.

Read move about the move and new location details.

13-Jun-12 3:00 PM

Liver Specialists of Texas Newsletter 2-Jun-12

Joseph Galati, M.D. - noemail@texasliver.com — Sat, 02 Jun 2012 06:02:06 GMT

Untitled Document

Welcome to the Liver Specialists of Texas newsletter of upcoming events, articles, jobs and more from our membership.

Calendar Events
Articles

Calendar Events for 2-Jun-12 to 1-Sep-12

Liver Specialists of Texas is Moving
Day: Thursday 14-Jun-12 8:00 AM to Monday 18-Jun-12 8:30 AM
Location: Liver Specialists of Texas 6560 Fannin Street, Suite 2050 Houston, TX 77030
Mapquest | Add to Calendar

Articles for 3-Apr-12 to 2-Jun-12

Colonoscopy Bowel Prep Video

This video shows the importance of following directions.

Colon Polyp Removal Video

This is a great video we produced showing the value of colonoscopy.

New Facts on HCV

The CDC released new recommendation regarding the testing of HCV, regardless of risk factors.

Frozen Fruits and Vegetable: A Great Alternative

Yes-frozen fruits and vegetables are healthful for you.

Portion Control Guide

A nice article from WebMD.

Remember, our office is moving June 14-18, 2012. Our office will be closed while we set up the new location. Our staff will be available through the answering servive around the clock for all our patients.

We are still evaluating patients for HCV research studies. You can contact Herman Ortiz in our research office. Both naive and retreatment protocols are available.

Remember: Colon Cancer is the third leading cancer in adults. It can be prevented with screening colonoscopy. Contact our office to make an appointment. All adults 50 years of age and older need to be screened; African Americans need to start screening at 45 years old. If you have a family history of colon cancer, you are at increased risk for developing colon cancer.

Your Health First, our weekly radio program, airs every Sunday evening at 7:00 p.m. on Clear Channel's 740 KTRH. It is also streamed on iHeart radio (www.iheartradio.com).

Stay up to date with our RSS feeds.

2-Jun-12 1:02 AM

Colonoscopy Preparation: Importance of Following Directions

Joseph Galati, M.D. - noemail@texasliver.com — Sat, 02 Jun 2012 04:00:00 GMT

This video shows you the importance of following directions while you prepare for a colonoscopy.

1-Jun-12 11:00 PM

Dr. Galati Discusses Fruits and Vegetables

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 29 Jan 2012 18:00:00 GMT

In this video blog, Dr. Joe Galati discusses frozen fruits and vegetables, and how to make the best selection at the food store.

View the You Tube Video here.

29-Jan-12 12:00 PM

Psychiatric Side Effects of Hepatitis C Therapy: Parts 1 and 2

Joseph Galati, M.D. - noemail@texasliver.com — Fri, 11 Nov 2011 14:00:00 GMT

Our latest video, as part of the Hepatitis C Education Program, is a two-part video featuring Dr. Jennifer Pate, a psychiatrist specializing in the care of patients with chronic liver disease.

The video blog can be viewed here for more details.

11-Nov-11 8:00 AM

Hepatitis C Treatment: Side Effects Management with Dr. Saira Khaderi

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 02 Oct 2011 04:00:00 GMT

In this You Tube video, Dr. Khaderi discussed several of the commonly encountered side effects related to hepatitis C therapy with interferon, ribavirin, and the new protease inhibitors.

To view the video on our You Tube Channel, click here.

1-Oct-11 11:00 PM

Liver Specialists of Texas Newsletter 21-Sep-11

Joseph Galati, M.D. - noemail@texasliver.com — Thu, 22 Sep 2011 13:03:30 GMT

Welcome to the Liver Specialists of Texas newsletter of upcoming events, articles, and more from our membership. We all appreciate your interest in our practice, and learning more about liver disease, new treatments that are available, health and wellness, and the prevention of disease.

Here is the latest from Liver Specialists of Texas.

Colon Cancer Video: Colon cancer is the number three cancer that adults are at risk for. We recently posted a video that is a perfect example of a patient who neglected rectal bleeding, only to find out there was a large polyp looming in his colon. To view the video, click here.

New Hepatitis C Research Opportunities: We continue to participate in clinical research studies for hepatitis C that are available for those either naive to HCV therapy (never treated) or those that have experience with therapy and never fully cleared the virus. One of the new studies is specificially researching African American and Latino adults with hepatitis C. If interested, you can contact our office for details. To learn more, click here.

Inside Look at Liver Transplant Surgery: View photographs of a liver transplant performed a couple of years ago, performed by Dr. Mark Ghobrial, and photographed by Dr. Galati. To view the video, click here.

New FDA Approved HCV Therapy-What You Need to Know, A Podcast: Listen to Dr. Galati discuss the new hepatitis C therapies recently FDA approved. Listed here.

Dietary Fiber: By request, one of the most popular downloads, this article reviewed a plan to increase your dietary fiber. With planning, you can increase your daily fiber to 30-40 grams. Start increasing your fiber by clicking here.

Tune in to Your Health First: Every Sunday evening at 7:00 p.m., tune into Your Health First, Dr. Galati's weekly radio program that discusses current health and wellness topics, with experts from around the world. Listen live at 740 KTRH or on the web at www.ktrh.com.

Staff Profile-Saira Khaderi, M.D.: Dr. Saira Khaderi has been with Liver Specialists of Texas for 1 year, and her presence has enhanced the patient experience greatly. Dr. Khaderi this year will be developing a specialized clinic for those individuals with non-alcoholic fatty liver disease. Deatails on this will follow in the next few months.

Stay up to date with our RSS feeds.

22-Sep-11 8:03 AM

Dr. Saira Khaderi Discussed Liver Disease

Joseph Galati, M.D. - noemail@texasliver.com — Tue, 17 May 2011 00:00:00 GMT

16-May-11 7:00 PM

Liver Specialists of Texas Newsletter 14-May-11

Joseph Galati, M.D. - noemail@texasliver.com — Sun, 15 May 2011 03:58:05 GMT

Welcome to the Liver Specialists of Texas newsletter of upcoming events, articles, jobs and more from our membership.

Yesterday, the FDA give approval to Boceprevir, the first in-class direct acting agent against hepatitis C. This is a long awaited announcement, and great news for patients and providers caring for hepatitis C. A You Tube video is available for review, with Dr. Galati's discussion of how patients will be evaluated and considered for treatment with Boceprevir.

Boceprevir Receives FDA Approval: A You Tube Video

A You Tube video of the announcement by Dr. Joe Galati is posted, discussing how Liver Specialists of Texas will evaluate and treat both new and old patients with Boceprevir. After years of research, and great anticipation by patients and physicians involved in the care of patients with hepatitis C, Boceprevier was finially approved yesterday. Yesterday was a very important day for those of us involved in the care of patients with hepatitis C, as well as the millions of... [More Info]

Conatus Continues New HCV Drug Development

A new financial report by Conatus, a company who is involved with HCV drug development, reports continued investment in their new HCV drugs. We are fortunate that we are conducting studies with their new agents, with good results. For more information, read the blog entry here.

New Hepatitis C Drug, Boceprevir, Features in New England Journal

Dr. Galati posted a blog entry from Berlin where he is attending the European Association for the Study of Liver Disease. Read the entire blog here.

Liver Specialists of Texas Supports The First Colony Dream League

Dr. Galati and Liver Specialists of Texas are 2011 supporters of the First Colony Dream League. First Colony Dream League is a Little League program in Sugar Land, Texas. The Dream League is a division of First Colony Little League (FCLL) and was established in Spring 2007. The Dream League roster is approximately 60 physically- and/or mentally- challenged players. In addition, the league has an Angels in the Outfield program, where approximately 150 teenage boys and girls from Ft.... [More Info]

OraSure Technologies Rapid Hepatitis C Test

OraSure Technologies Rapid Hepatitis C Test has been submitted to the FDA for a CLIA waiver, which would allow greater availability to this screening hepatitis C test for those at risk for hepatitis C. Read Dr. Galati's blog entry for more details.

The Five Most Common Questions Liver Transplant Patients Ask Dr. Galati

Dr. Galati recently narrated this You Tube video on The Five Most Common Questions Liver Transplant Patients Ask. If you have additional questions, contact us.

Telaprevir and Boceprevir: FDA Approval Soon

There is great excitement regarding the soon to be FDA approval of both Telaprevir and Boceprevir, in the treatment of chronic heaptitis C. Read here for more information on Dr. Galati's opinion on what will be coming later this summer.

Stay up to date with our RSS feeds.

14-May-11 10:58 PM

Boceprevir Receives FDA Approval: A You Tube Video

Dr. Joseph Galati Galati - noemail@texasliver.com — Sun, 15 May 2011 01:30:00 GMT

A You Tube video of the announcement by Dr. Joe Galati is posted, discussing how Liver Specialists of Texas will evaluate and treat both new and old patients with Boceprevir.

After years of research, and great anticipation by patients and physicians involved in the care of patients with hepatitis C, Boceprevier was finially approved yesterday.

Yesterday was a very important day for those of us involved in the care of patients with hepatitis C, as well as the millions of individuals affected by it. I received word yesterday afternoon that the FDA has approved boceprevir for the treatment of G1 CHC in previously untreated patients and patients who have failed previous interferon and ribavirin therapy. Boceprevir is the first in class direct acting antiviral to be FDA approved for CHC. Manufactured by Merck pharmaceutical company, the new drug will be commercially available by the name VICTRELIS.

It is expected that VICTRELIS will be available in your local pharmacy very soon.

Keep in mind these new protease inhibitors are given in combination with interferon and ribavirin.

For the first time in nearly 10 years, we have a new drug to treat and cure those with hepatitis C. The clinical research leading up to its approval is stunning, with the highest success rates ever seen in hepatitis C. This is truly a landmark breakthrough in medicine. For those waiting for “the new drugs to treat hepatitis C”, you day has come.

For those patients of ours at Liver Specialists of Texas, I anticipate to be hearing from all of you very soon. It will take time to get all of you scheduled and seen by our hepatitis C treatment team. Call our office to get the ball rolling, and in the meantime, I’d ask that you do the following:

Make sure you have all of your old records related to past hepatitis C treatments. It is important to see how you responded previously, and what special attention you may need as we re-treat you.
If you have had a prior liver biopsy, an outside facility, do your best to get a copy of the report.
When you call the office, we need to know if you have been treated in the past, or naïve (never treated) for hepatitis C.
If you have been treated, we’d like to know your past response to therapy.
Were you a null responder, non-responder, or a responder relapser. Again, this will help tailor how you will be treated.
When speaking with our staff, let us know if you have diabetes, heart disease, kidney disease, or received a prior liver or kidney transplant. The more information we have about you, the better we can care for you.

In the next few days, we will have posted on the web a hepatitis C questionnaire, dealing with some of these issues just mentioned. All of are looking forward to an orderly evaluation process for our patients.

If you are going to be new to our practice, additional intake information will be needed and forwarded to you.

All of us at Liver Specialists of Texas are very happy with these developments, and we look forward to caring for you.

Visit our website often as new information will be posted daily.

14-May-11 8:30 PM

Conatus Continues New HCV Drug Development

Dr. Joseph Galati - noemail@texasliver.com — Thu, 14 Apr 2011 17:00:00 GMT

For more information, read the blog entry here.

14-Apr-11 12:00 PM

New Hepatitis C Drug, Boceprevir, Features in New England Journal

Dr. Joseph Galati Galati - noemail@texasliver.com — Thu, 31 Mar 2011 23:00:00 GMT

Dr. Galati posted a blog entry from Berlin where he is attending the European Association for the Study of Liver Disease. Read the entire blog here.

31-Mar-11 6:00 PM

Liver Specialists of Texas Supports The First Colony Dream League

Dr. Joseph Galati Galati - noemail@texasliver.com — Sun, 27 Mar 2011 19:00:00 GMT

Dr. Galati and Liver Specialists of Texas are 2011 supporters of the First Colony Dream League.

First Colony Dream League is a Little League program in Sugar Land, Texas. The Dream League is a division of First Colony Little League (FCLL) and was established in Spring 2007. The Dream League roster is approximately 60 physically- and/or mentally- challenged players. In addition, the league has an "Angels in the Outfield" program, where approximately 150 teenage boys and girls from Ft. Bend area schools volunteer to assist Dream League players during the game, becoming a loyal buddy in the process.

View the opening day video here.

27-Mar-11 2:00 PM

OraSure Technologies Rapid Hepatitis C Test

Dr. Joseph Galati Galati - noemail@texasliver.com — Thu, 24 Mar 2011 23:00:00 GMT

Read Dr. Galati's blog entry for more details.

24-Mar-11 6:00 PM

The Five Most Common Questions Liver Transplant Patients Ask Dr. Galati

Joseph Galati, M.D. - noemail@texasliver.com — Wed, 16 Mar 2011 02:00:00 GMT

Dr. Galati recently narrated this You Tube video on The Five Most Common Questions Liver Transplant Patients Ask.

If you have additional questions, contact us.

15-Mar-11 9:00 PM

Telaprevir and Boceprevir: FDA Approval Soon

Dr. Joseph Galati Galati - noemail@texasliver.com — Tue, 01 Mar 2011 01:00:00 GMT

There is great excitement regarding the soon to be FDA approval of both Telaprevir and Boceprevir, in the treatment of chronic heaptitis C.

Read here for more information on Dr. Galati's opinion on what will be coming later this summer.

28-Feb-11 7:00 PM

Liver Specialists of Texas Newsletter 14-Jan-11

Dr. Joseph Galati Galati - noemail@texasliver.com — Fri, 14 Jan 2011 22:11:06 GMT

Welcome to the Liver Specialists of Texas newsletter of upcoming events, articles, jobs and more from our membership.

Access To Your Medical Records SoonTo Be Available

In the next several days, acces to your medical records will be available for those that are patients of our practice at Liver Specialists of Texas. Through eMDs, the electronic medical record that we use, a patient portal will be established. Before logging into the portal, you must first be issues a login and password. This can be done by first filling out this electronic release... [More Info]

Don't Eat At Olive Garden

Dr. Joe Galati spoke about an experience at an Olive Garden Resturant recently on his radio program Your Health First several months ago.

Colon Cancer Interview With Dr. Joe Galati

This is an archived radio interview and podcast Dr. Galati performed a few years ago during an episode of Your Health First, his weekly radio program on Clear Channel's 740 KTRH. He was discussing colon cancer with two patients who have an interesting story to tell regarding colon cancer. The podcast can be listed to by going to the podcast page, where you will see all of the podcast episodes.

Visit the Liver Specialists of Texas blog here

Stay up to date with our RSS feeds.

14-Jan-11 4:11 PM

Access To Your Medical Records SoonTo Be Available

Dr. Joseph Galati Galati - noemail@texasliver.com — Mon, 10 Jan 2011 20:00:00 GMT

Before logging into the portal, you must first be issues a login and password. This can be done by first filling out this electronic release form that our office must process. It only takes a few minutes, but is the first step to accessing your files. The release form can be downloaded here.

The Patient Portal is a web-based system that serves as a secure communication link between you and the clinic. When you log in to the Portal with your private user name and password, you can see information that is pulled from your electronic record at the clinic and displayed on the web page.

After logging in to Portal, you can:

•Use the messaging feature to communicate with clinic staff.

•View your health summary information.

•Send health summary information update requests if you notice missing information.

•View results of lab and other diagnostic tests.

•Schedule, confirm, cancel, or reschedule an appointment.

•Add an appointment request to your wait list.

•Request a referral or a medication refill.

Print or save an electronic copy of your Health Summary using the standard Continuity of Care Record (CCR) format.

To access the patient portal, you start by heading to our practice website. On the homepage, there is a new login link that will take you to the patient portal entry.

Instructions posted below with the attached PDF file can guide you through the login process.

Prior to obtaining permission, you will need to receive a secure password that allows you entry into the system.

10-Jan-11 2:00 PM